Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

60 is the new 40 in heart failure

Christina Lau
02 Jan 2020

A left ventricular ejection fraction (LVEF) cut-off of 60 percent may identify patients with heart failure (HF) with mid-range or preserved ejection fraction (mrEF or pEF) who could benefit from drug therapy.

“In recent clinical trials in patients with HFmrEF or HFpEF, we have seen benefit of the evaluated therapies until LVEF reaches 60 percent. Therefore, in my opinion, 60 is the new 40 in HF,” said Professor Marc Pfeffer of Harvard Medical School, Boston, Massachusetts, US.

In the PARAGON-HF trial in patients with HFpEF (LVEF ≥45 percent), the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan significantly reduced the risk of the primary composite outcome (total HF hospitalizations and cardiovascular [CV] death) vs valsartan alone in the subgroup of patients with LVEF ≤57 percent (rate ratio [RR], 0.78; 95 percent confidence interval [CI], 0.64 to 0.95), but not in those with LVEF >57 percent (RR, 1.00; 95 percent CI, 0.81 to 1.23). [N Engl J Med 2019;38:1609-1620]

A combined analysis of data from the PARADIGM-HF (LVEF eligibility, ≤40 percent) and PARAGON-HF trials showed that the treatment effect of sacubitril/valsartan vs a renin-angiotensin-system (RAS) inhibitor alone decreased with increasing LVEF. “In terms of the composite outcome of total HF hospitalizations and CV death, no benefit was seen in patents with LVEF ≥60 percent,” noted Pfeffer. [Circulation 2019, doi: 10.1161/CIRCULATIONAHA.119.044586]

“This loss of treatment benefit at LVEF ≥60 percent was also observed in the CHARM trial of candesartan in HFmrEF [LVEF 40–49 percent] and the TOPCAT trial of spironolactone in HFpEF [LVEF ≥45 percent],” he pointed out. [Eur J Heart Fail 2018;20:1230-1239; Eur Heart J 2016;37:455-462]

“These results suggest that for patients with HF with LVEF <60 percent, the benefits of HF therapy would outweigh the risks, costs and inconvenience associated with treatment,” he suggested.

The therapeutic armamentarium for HFpEF may expand as drugs from various classes are being evaluated in large, ongoing clinical trials. For example, sodium-glucose cotransporter-2 (SGLT2) inhibitors and spironolactone are being studied for their effect on HFpEF outcomes. Sacubitril/valsartan is also being evaluated, against individualized medical therapy, for its effect in lowering N-terminal pro-B-type natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with HFpEF in the PARALLAX trial.

“This is now the most exciting time for HF management,” said Pfeffer.

“In patients with HFpEF, I do use spironolactone because it is inexpensive and significantly reduces HF hospitalizations. An exploratory post-hoc analysis of the TOPCAT trial showed that it significantly reduces CV death and HF hospitalizations in patients from the Americas,” he added. [N Engl J Med 2014;370:1383-1892; Circulation 2015;131:34-42]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.